Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Weiner

Showing results (61-70 of 133) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for PatientsCarlos L Arteaga, John L Cleveland, Margaret Foti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Translational Research Working Group developmental pathway for immune response modifiersMartin A Cheever, Jeffrey Schlom, Louis M Weiner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 4, 2020
Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding PredictionsMichelle P Aranha, Yead S M Jewel, Robert A Beckman, et al.
American Journal of Clinical Oncology|April 1, 2008
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumorsSteven J Cohen, Paul F Engstrom, Nancy L Lewis, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2015
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesMargaret von Mehren, Michael Bookman, Neal J Meropol, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 26, 2007
Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology GroupHossein Borghaei, R Katherine Alpaugh, Patricia Bernardo, et al.
Genome Medicine|August 11, 2021
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumorsEmily F Davis-Marcisak, Allison A Fitzgerald, Michael D Kessler, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2015
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancerZheng Wu, Andrew Gabrielson, Jimmy J Hwang, et al.
Methods (San Diego, Calif.)|June 28, 2017
Protein network construction using reverse phase protein array dataRency S Varghese, Yiming Zuo, Yi Zhao, et al.
Cancer Research|March 17, 2011
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumorsStephen I Rudnick, Jianlong Lou, Calvin C Shaller, et al.
Pageof 14

Showing results (61-70 of 133) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2023
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for PatientsCarlos L Arteaga, John L Cleveland, Margaret Foti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Translational Research Working Group developmental pathway for immune response modifiersMartin A Cheever, Jeffrey Schlom, Louis M Weiner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 4, 2020
Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding PredictionsMichelle P Aranha, Yead S M Jewel, Robert A Beckman, et al.
American Journal of Clinical Oncology|April 1, 2008
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumorsSteven J Cohen, Paul F Engstrom, Nancy L Lewis, et al.
Cancer Chemotherapy and Pharmacology|March 21, 2015
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignanciesMargaret von Mehren, Michael Bookman, Neal J Meropol, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 26, 2007
Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology GroupHossein Borghaei, R Katherine Alpaugh, Patricia Bernardo, et al.
Genome Medicine|August 11, 2021
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumorsEmily F Davis-Marcisak, Allison A Fitzgerald, Michael D Kessler, et al.
Cancer Chemotherapy and Pharmacology|October 29, 2015
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancerZheng Wu, Andrew Gabrielson, Jimmy J Hwang, et al.
Methods (San Diego, Calif.)|June 28, 2017
Protein network construction using reverse phase protein array dataRency S Varghese, Yiming Zuo, Yi Zhao, et al.
Cancer Research|March 17, 2011
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumorsStephen I Rudnick, Jianlong Lou, Calvin C Shaller, et al.
Pageof 14